CA125/MUC16 Antibody (oregovomab) [Allophycocyanin]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28081APC
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
ELISA, Flow Cytometry, Functional
Label
Allophycocyanin (Excitation = 620-650 nm, Emission = 660-670 nm)
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # oregovomab
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for CA125/MUC16 Antibody (oregovomab) [Allophycocyanin]
Immunogen
MUC16
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for CA125/MUC16 Antibody (oregovomab) [Allophycocyanin]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CA125/MUC16
Long Name
Ovarian Cancer Antigen CA125
Alternate Names
MUC16
Gene Symbol
MUC16
Additional CA125/MUC16 Products
Product Documents for CA125/MUC16 Antibody (oregovomab) [Allophycocyanin]
Product Specific Notices for CA125/MUC16 Antibody (oregovomab) [Allophycocyanin]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...